Literature DB >> 16534552

Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology.

Anthony F Shields1.   

Abstract

This work highlights the explosion and evolution of positron emission tomography (PET) for use in oncology research and clinical practice. 2-Deoxy-2-[F-18]fluoro-D-glucose (FDG)-PET is important in the staging of cancer, estimation of prognosis, and for its ability to predict therapeutic outcome. A number of new imaging agents are under development and may find a place in oncology when studies prove their utility. This scientific overview includes a review of the development of a number of thymidine analogs, such as 18F-3'-deoxy-3'-fluorothymidine (FLT) and 18F-1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-thymine (FMAU), including chemical structure variations; their application in a variety of tumors; and the role of various kinetic models for understanding cellular proliferation. The greatest unmet need for PET is in further developing and validating its use in the measurement of treatment response.

Entities:  

Mesh：

Year:  2006        PMID： 16534552     DOI： 10.1007/s11307-006-0039-2

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN： 1536-1632            Impact factor:   3.488


  57 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.

Authors:  Lale Kostakoglu; Morton Coleman; John P Leonard; Ichiei Kuji; Holly Zoe; Stanley J Goldsmith
Journal:  J Nucl Med       Date:  2002-08       Impact factor: 10.057

3.  11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.

Authors:  Nobuyuki Oyama; Tom R Miller; Farrokh Dehdashti; Barry A Siegel; Keith C Fischer; Jeff M Michalski; Adam S Kibel; Gerald L Andriole; Joel Picus; Michael J Welch
Journal:  J Nucl Med       Date:  2003-04       Impact factor: 10.057

4.  3'-Deoxy-3'-fluorothymidine, a new selective inhibitor of DNA-synthesis.

Authors:  P Langen; G Etzold; R Hintsche; G Kowollik
Journal:  Acta Biol Med Ger       Date:  1969

5.  Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens?

Authors:  Chandra N Burge; Helena R Chang; Sophia K Apple
Journal:  Breast       Date:  2005-08-10       Impact factor: 4.380

6.  Reproducibility of metabolic measurements in malignant tumors using FDG PET.

Authors:  W A Weber; S I Ziegler; R Thödtmann; A R Hanauske; M Schwaiger
Journal:  J Nucl Med       Date:  1999-11       Impact factor: 10.057

7.  Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.

Authors:  Susanne-Martina Eschmann; Frank Paulsen; Matthias Reimold; Helmut Dittmann; Stefan Welz; Gerald Reischl; Hans-Juergen Machulla; Roland Bares
Journal:  J Nucl Med       Date:  2005-02       Impact factor: 10.057

8.  Brain tumor imaging with PET and 2-[carbon-11]thymidine.

Authors:  T Vander Borght; S Pauwels; L Lambotte; D Labar; S De Maeght; G Stroobandt; C Laterre
Journal:  J Nucl Med       Date:  1994-06       Impact factor: 10.057

9.  Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography.

Authors:  W J Koh; K S Bergman; J S Rasey; L M Peterson; M L Evans; M M Graham; J R Grierson; K L Lindsley; T K Lewellen; K A Krohn
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-09-30       Impact factor: 7.038

Review 10.  Noninvasive staging of non-small cell lung cancer: a review of the current evidence.

Authors:  Eric M Toloza; Linda Harpole; Douglas C McCrory
Journal:  Chest       Date:  2003-01       Impact factor: 9.410
View more
  39 in total

1.  Pharmacodynamic evaluation of irinotecan therapy by FDG and FLT PET/CT imaging in a colorectal cancer xenograft model.

Authors:  Sarah R Mudd; Kimberley D Holich; Martin J Voorbach; Todd B Cole; David R Reuter; Paul Tapang; Gail Bukofzer; Arunava Chakravartty; Cherrie K Donawho; Joann P Palma; Gerard B Fox; Mark Day; Yanping Luo
Journal:  Mol Imaging Biol       Date:  2012-10       Impact factor: 3.488

Review 2.  Applications of molecular imaging.

Authors:  Craig J Galbán; Stefanie Galbán; Marcian E Van Dort; Gary D Luker; Mahaveer S Bhojani; Alnawaz Rehemtulla; Brian D Ross
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

3.  Scaling of number, size, and metabolic rate of cells with body size in mammals.

Authors:  Van M Savage; Andrew P Allen; James H Brown; James F Gillooly; Alexander B Herman; William H Woodruff; Geoffrey B West
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-01       Impact factor: 11.205

Review 4.  Positron emission tomography imaging of cancer biology: current status and future prospects.

Authors:  Kai Chen; Xiaoyuan Chen
Journal:  Semin Oncol       Date:  2011-02       Impact factor: 4.929

5.  ¹⁸F-FDG PET/CT-based treatment response evaluation in locally advanced rectal cancer: a prospective validation of long-term outcomes.

Authors:  Felipe A Calvo; Claudio V Sole; Dolores de la Mata; Luis Cabezón; Marina Gómez-Espí; Emilio Alvarez; Paz Madariaga; José L Carreras
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-23       Impact factor: 9.236

Review 6.  Molecular imaging of prostate cancer: PET radiotracers.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2012-08       Impact factor: 3.959

7.  Clinical significance of VEGFR-2 and ¹⁸F-FDG PET/CT SUVmax pretreatment score in predicting the long-term outcome of patients with locally advanced rectal cancer treated with neoadjuvant therapy.

Authors:  Claudio V Sole; Felipe A Calvo; Emilio Alvarez; Isabel Peligros; Pilar Garcia-Alfonso; Carlos Ferrer; Enrique Ochoa; Rafael Herranz; Jose L Carreras
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-06-26       Impact factor: 9.236

Review 8.  PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer.

Authors:  Hossein Jadvar
Journal:  J Nucl Med       Date:  2016-10       Impact factor: 10.057

Review 9.  Use of radionuclides in cancer research and treatment.

Authors:  M T Macías
Journal:  Clin Transl Oncol       Date:  2009-03       Impact factor: 3.405

10.  Initial characterization of a dually radiolabeled peptide for simultaneous monitoring of protein targets and enzymatic activity.

Authors:  Efrem Mebrahtu; Alexander Zheleznyak; Minjun A Hur; Richard Laforest; Suzanne E Lapi
Journal:  Nucl Med Biol       Date:  2012-11-12       Impact factor: 2.408
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.